Pfizer Mum On Consumer Business Plans As Analysts Say Spin-off

Pfizer continues to review options for its consumer business, though analysts say a spin-off makes most sense. During its fourth-quarter earnings call, firm reported the division's US sales slumped 9% but 12% growth in international markets buoyed the worldwide results.

On the eve of Pfizer Inc.’sdeadline for bids for its consumer health business, the firm gave no indication whether it will follow through on potentially selling the division. Most analysts are recommending a spin-off.

During Pfizer's 2017 fourth-quarter and full-year earnings briefing on Jan. 30, CEO Ian Read said "strategic options" for the business...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from International

More from Geography